DE60208701D1 - Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom - Google Patents

Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom

Info

Publication number
DE60208701D1
DE60208701D1 DE60208701T DE60208701T DE60208701D1 DE 60208701 D1 DE60208701 D1 DE 60208701D1 DE 60208701 T DE60208701 T DE 60208701T DE 60208701 T DE60208701 T DE 60208701T DE 60208701 D1 DE60208701 D1 DE 60208701D1
Authority
DE
Germany
Prior art keywords
cetrorelix
creutzfeldt
jakob
syndrome
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60208701T
Other languages
English (en)
Other versions
DE60208701T2 (de
Inventor
Juergen Engel
Manfred Peukert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Zentaris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris AG filed Critical Zentaris AG
Priority to DE60208701T priority Critical patent/DE60208701T2/de
Publication of DE60208701D1 publication Critical patent/DE60208701D1/de
Application granted granted Critical
Publication of DE60208701T2 publication Critical patent/DE60208701T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60208701T 2001-07-31 2002-07-30 Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom Expired - Fee Related DE60208701T2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE60208701T DE60208701T2 (de) 2001-07-31 2002-07-30 Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10137174A DE10137174A1 (de) 2001-07-31 2001-07-31 Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
DE10137174 2001-07-31
DE60208701T DE60208701T2 (de) 2001-07-31 2002-07-30 Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom
PCT/EP2002/008459 WO2003011314A2 (en) 2001-07-31 2002-07-30 Use of lhrh-antagonists for the improvement of t-cell mediated immunity

Publications (2)

Publication Number Publication Date
DE60208701D1 true DE60208701D1 (de) 2006-04-06
DE60208701T2 DE60208701T2 (de) 2006-08-10

Family

ID=7693650

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10137174A Withdrawn DE10137174A1 (de) 2001-07-31 2001-07-31 Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
DE60208701T Expired - Fee Related DE60208701T2 (de) 2001-07-31 2002-07-30 Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE10137174A Withdrawn DE10137174A1 (de) 2001-07-31 2001-07-31 Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität

Country Status (19)

Country Link
EP (1) EP1414481B1 (de)
JP (1) JP2005500348A (de)
KR (1) KR20040028957A (de)
CN (1) CN1525865A (de)
AR (1) AR034954A1 (de)
AT (1) ATE315400T1 (de)
BR (1) BR0211498A (de)
CA (1) CA2452524A1 (de)
DE (2) DE10137174A1 (de)
HR (1) HRP20040186B1 (de)
HU (1) HUP0401634A2 (de)
IL (1) IL159285A0 (de)
MX (1) MXPA04000870A (de)
NO (1) NO20040350L (de)
NZ (1) NZ531263A (de)
PL (1) PL364492A1 (de)
RU (1) RU2004106545A (de)
WO (1) WO2003011314A2 (de)
ZA (1) ZA200309889B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
EP1891964A1 (de) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Anwendung von Anfangsdosen von LHRH-Analogen und Erhaltungsdosen von LHRH-Antagonisten zur Behandlung von hormonabhängigen Krebsarten und entsprechende Kits
RU2010113977A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение антагониста рецептора фибриногена и/или пептид фолликулярного гонадолиберина в качестве терапевтического средства при лечении инфекции streptococcus pneumoniae
WO2009043455A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Therapeutic uses of angiogenin 108-122 and gluten exorphin a5
EP2095818A1 (de) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Verwendung von LHRH-Antagonisten in nicht-kastrierenden Dosen
CA2750582A1 (en) * 2009-01-22 2010-07-29 Maatschap Interne Geneeskunde Rijnstate Method for the prophylaxis or treatment of flushing
CA2958939A1 (en) 2014-08-26 2016-03-03 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
CN107007814B (zh) * 2016-11-04 2020-03-17 中国科学院昆明动物研究所 西曲瑞克在制备治疗艾滋病的药物中的应用
CN108066763A (zh) * 2017-12-21 2018-05-25 陈敏 Pcsk9抑制剂在制备治疗t细胞介导的炎症免疫性疾病药中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04504760A (ja) * 1989-09-25 1992-08-20 アメリカ合衆国 炎症性反応の検出およびストレスに対する応答の予測をするための評価方法
DE4320201A1 (de) * 1993-06-18 1995-01-12 Asta Medica Ag Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
DE4342091A1 (de) * 1993-12-09 1995-06-14 Asta Medica Ag Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten
CN1137722C (zh) * 1994-07-22 2004-02-11 汉普顿路医学院 为长期治疗方案确立基础(tonic)卵巢雌激素分泌
CA2173727A1 (en) * 1994-08-10 1996-02-22 Sandor Lovas Novel gnrh analogues with antitumour effects and pharmaceutical compositions thereof
WO1996022786A1 (en) * 1995-01-23 1996-08-01 Takeda Chemical Industries, Ltd. Sustained-release preparation and use
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
CA2309855A1 (en) * 1997-11-24 1999-06-03 Katherine D. Gordon Testosterone inhibitors and use for the protection of neurons
US20020071829A1 (en) * 1999-04-15 2002-06-13 Richard Boyd Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20020119128A1 (en) * 2000-04-17 2002-08-29 Richard Boyd Graft acceptance through manipulation of thymic regeneration
WO2001078780A1 (fr) * 2000-04-13 2001-10-25 Takeda Chemical Industries, Ltd. Agents preventifs/remedes pour la maladie d'alzheimer
EP1392348B1 (de) * 2001-04-30 2008-07-09 AEterna Zentaris GmbH Niedrigdosierte lhrh antagonisten zur behandlung von neurodegenerativen krankheiten, insbesondere alzheimer krankheit
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence

Also Published As

Publication number Publication date
ZA200309889B (en) 2004-02-19
ATE315400T1 (de) 2006-02-15
WO2003011314A2 (en) 2003-02-13
DE10137174A1 (de) 2003-02-13
WO2003011314A3 (en) 2003-10-16
RU2004106545A (ru) 2005-04-10
NZ531263A (en) 2005-05-27
JP2005500348A (ja) 2005-01-06
AR034954A1 (es) 2004-03-24
CA2452524A1 (en) 2003-02-13
DE60208701T2 (de) 2006-08-10
HRP20040186A2 (en) 2004-08-31
IL159285A0 (en) 2004-06-01
NO20040350L (no) 2004-01-26
EP1414481A2 (de) 2004-05-06
KR20040028957A (ko) 2004-04-03
CN1525865A (zh) 2004-09-01
PL364492A1 (en) 2004-12-13
HUP0401634A2 (hu) 2004-12-28
BR0211498A (pt) 2004-08-17
MXPA04000870A (es) 2004-06-03
HRP20040186B1 (en) 2007-05-31
EP1414481B1 (de) 2006-01-11

Similar Documents

Publication Publication Date Title
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DE60230425D1 (de) Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
DE69910368D1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
DE60335560D1 (de) Zusammensetzungen enthaltend zitronensäure zur behandlung von nagelpilzerkrankungen
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE60113496D1 (de) Verwendung von Glycyrrhizin zur Behandlung von Mastitis.
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE50214540D1 (de) Stanz bei der behandlung von wunden
DE60234760D1 (de) Phenylindole zur behandlung von hiv
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE369130T1 (de) Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
DE60239220D1 (de) ClC-2-KANALÖFFNER ZUR BEHANDLUNG VON MAGEN- ODER DARM-ULCUS
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE60328494D1 (de) Verbessertes system zur behandlung der stressbedingten harninkontinenz
DE60208701D1 (de) Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
ATE337787T1 (de) Exemestan zur behandlung von hormonabhängigen störungen
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AETERNA ZENTARIS GMBH, 60314 FRANKFURT, DE

8339 Ceased/non-payment of the annual fee